Advertisement

Primary Carnitine Deficiency: Is Foetal Development Affected and Can Newborn Screening Be Improved?

  • Jan RasmussenEmail author
  • David M. Hougaard
  • Noreen Sandhu
  • Katrine Fjællegaard
  • Poula R. Petersen
  • Ulrike Steuerwald
  • Allan M. Lund
Research Report
Part of the JIMD Reports book series (JIMD, volume 36)

Abstract

Primary carnitine deficiency (PCD) causes low levels of carnitine in patients potentially leading to metabolic and cardiac symptoms. Newborn screening for PCD is now routine in many countries by measuring carnitine levels in infants. In this study we report Apgar scores, length and weight in newborns with PCD and newborns born to mothers with PCD compared to controls. Furthermore we report how effective different screening algorithms have been to detect newborns with PCD in the Faroe Islands.

Results: Newborns with PCD and newborns born to mothers with PCD did not differ with regard to Apgar scores, length and weight compared to controls. Newborns with PCD and newborns born to mothers with PCD had significantly lower levels of free carnitine (fC0) than controls. Screening algorithms focusing only on fC0 had a high rate of detection of newborns with PCD. Sample collection 4–9 days after birth seems to result in a higher detection rate than the current 2–3 days.

Conclusion: The clinical status at birth in infants with PCD and infants born to mothers with PCD does not differ compared to control infants. Screening algorithms for PCD should focus on fC0, and blood samples should be taken when the maternal influence on fC0 has diminished.

Keywords

Apgar Faroe Islands Newborn screening Primary carnitine deficiency 

Notes

Acknowledgements

The authors would like to thank the laboratory in the National Hospital in the Faroe Islands.

References

  1. Als TD, Jorgensen TH, Borglum AD et al (2006) Highly discrepant proportions of female and male Scandinavian and British Isles ancestry within the isolated population of the Faroe Islands. Eur J Hum Genet 14(4):497–504CrossRefPubMedGoogle Scholar
  2. Apgar V (1953) A proposal for a new method of evaluation of the newborn infant. Curr Res Anesth Analg 32(4):260–267PubMedGoogle Scholar
  3. Fingerhut R, Ensenauer R, Roschinger W et al (2009) Stability of acylcarnitines and free carnitine in dried blood samples: implications for retrospective diagnosis of inborn errors of metabolism and neonatal screening for carnitine transporter deficiency. Anal Chem 81(9):3571–3575CrossRefPubMedGoogle Scholar
  4. Finster M, Wood M (2005) The Apgar score has survived the test of time. Anesthesiology 102(4):855–857CrossRefPubMedGoogle Scholar
  5. Jorgensen TH, Degn B, Wang AG et al (2002) Linkage disequilibrium and demographic history of the isolated population of the Faroe Islands. Eur J Hum Genet 10(6):381–387CrossRefPubMedGoogle Scholar
  6. Jorgensen TH, Buttenschon HN, Wang AG et al (2004) The origin of the isolated population of the Faroe Islands investigated using Y chromosomal markers. Hum Genet 115(1):19–28CrossRefPubMedGoogle Scholar
  7. Koizumi A, Nozaki J, Ohura T et al (1999) Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Hum Mol Genet 8(12):2247–2254CrossRefPubMedGoogle Scholar
  8. Longo N, Amat di San Filippo C, Pasquali M (2006) Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 142C(2):77–85CrossRefPubMedPubMedCentralGoogle Scholar
  9. Lund AM, Hougaard DM, Simonsen H et al (2012) Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland – experience and development of a routine program for expanded newborn screening. Mol Genet Metab 107(3):281–293CrossRefPubMedGoogle Scholar
  10. Magoulas PL, El-Hattab AW (2012) Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 7:68CrossRefPubMedPubMedCentralGoogle Scholar
  11. Nezu J, Tamai I, Oku A et al (1999) Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 21(1):91–94CrossRefPubMedGoogle Scholar
  12. Norgaard-Pedersen B, Hougaard DM (2007) Storage policies and use of the Danish Newborn Screening Biobank. J Inherit Metab Dis 30(4):530–536CrossRefPubMedGoogle Scholar
  13. Norgaard-Pedersen B, Simonsen H (1999) Biological specimen banks in neonatal screening. Acta paediatr Suppl 88(432):106–109CrossRefPubMedGoogle Scholar
  14. Novak M, Monkus EF, Chung D et al (1981) Carnitine in the perinatal metabolism of lipids. I. Relationship between maternal and fetal plasma levels of carnitine and acylcarnitines. Pediatrics 67(1):95–100PubMedGoogle Scholar
  15. Pasquali M, Longo N (2013) Response to chen et Al.: carnitine uptake defect (primary carnitine deficiency): risk in genotype-phenotype correlation. Hum Mutat 34(4):656CrossRefPubMedGoogle Scholar
  16. Rasmussen J, Nielsen OW, Lund AM et al (2013) Primary carnitine deficiency and pivalic acid exposure causing encephalopathy and fatal cardiac events. J Inherit Metab Dis 36(1):35–41CrossRefPubMedGoogle Scholar
  17. Rasmussen J, Nielsen OW, Janzen N et al (2014a) Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands. J Inherit Metab Dis 37(2):215–222CrossRefPubMedGoogle Scholar
  18. Rasmussen J, Kober L, Lund AM et al (2014b) Primary carnitine deficiency in the Faroe Islands: health and cardiac status in 76 adult patients diagnosed by screening. J Inherit Metab Dis 37(2):223–230CrossRefPubMedGoogle Scholar
  19. Rasmussen J, Lund AM, Risom L et al (2014c) Residual OCTN2 transporter activity, carnitine levels and symptoms correlate in patients with primary carnitine deficiency. Mol Genet Metab Rep 1:241–248CrossRefPubMedPubMedCentralGoogle Scholar
  20. Rasmussen J, Thomsen JA, Olesen JH et al (2015) Carnitine levels in skeletal muscle, blood and urine in patients with primary carnitine deficiency during intermission with L-carnitine supplementation. JIMD Rep 20:103–111CrossRefPubMedPubMedCentralGoogle Scholar
  21. Scaglia F, Wang Y, Singh RH et al (1998) Defective urinary carnitine transport in heterozygotes for primary carnitine deficiency. Genet Med 1(1):34–39CrossRefPubMedGoogle Scholar
  22. Stanley CA (2004) Carnitine deficiency disorders in children. Ann N Y Acad Sci 1033:42–51CrossRefPubMedGoogle Scholar
  23. Strnadova KA, Holub M, Muhl A et al (2007) Long-term stability of amino acids and acylcarnitines in dried blood spots. Clin Chem 53(4):717–722CrossRefPubMedGoogle Scholar
  24. Tein I (2003) Carnitine transport: pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis 26(2–3):147–169CrossRefPubMedGoogle Scholar
  25. Wilcken B, Wiley V, Hammond J et al (2003) Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 348(23):2304–2312CrossRefPubMedGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Jan Rasmussen
    • 1
    Email author
  • David M. Hougaard
    • 2
  • Noreen Sandhu
    • 2
  • Katrine Fjællegaard
    • 1
  • Poula R. Petersen
    • 1
  • Ulrike Steuerwald
    • 3
    • 4
  • Allan M. Lund
    • 5
  1. 1.Department of Internal MedicineNational HospitalTorshavnFaroe Islands
  2. 2.Section of Neonatal Screening and Hormones, Department for Congenital DisordersStatens Serum InstitutCopenhagenDenmark
  3. 3.Department of Occupational and Public HealthNational Hospital SystemTorshavnFaroe Islands
  4. 4.Screening-Laboratories HannoverHannoverGermany
  5. 5.Centre for Inherited Metabolic Diseases, Department of Clinical GeneticsCopenhagen University HospitalCopenhagenDenmark

Personalised recommendations